logo
Plus   Neg
Share
Email

United Technologies Boosts FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter, United Technologies Corp. (UTX) on Tuesday increased its full-year 2019 guidance for adjusted earnings, while maintaining its sales outlook for the full year.

For fiscal 2019, the company raised its guidance for adjusted earnings to a range of $7.90 to $8.05 per share from the prior forecast range of $7.80 to $8.00 per share.

However, the company maintained its previous outlook for sales to be between $75.5 billion and $77.0 billion, but raised organic sales growth guidance range to 4 to 5 percent, up from 3 to 5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.97 per share on sales of $77.23 billion for the year. Analysts' estimates typically exclude special items.

"Looking ahead, we remain on track to establish Otis and Carrier as independent companies in the first half of 2020. We are also excited about the transformational merger with Raytheon that we announced in June, which will create a leading, platform-agnostic aerospace and defense systems company ," said Chairman and CEO Gregory Hayes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT